Unravelling the Politics Behind India’s PM-JAY Health Insurance Scheme

By HEOR Staff Writer

July 26, 2023

The PM-JAY health insurance scheme, launched in India in 2018, was a crucial step towards universal health coverage (UHC). The policy’s design was shaped by a mix of technical and political elements, with a focus on bureaucratic aspects rather than ideological ones. The scheme was introduced by the ruling government just before national elections, leveraging policy legacies from previous and state insurance schemes. Key decisions such as the coverage amount and portability of benefits were centrally driven, while inputs from Indian states influenced features like the mode of implementation and provider network. This balanced approach facilitated the adoption of the reform. However, the scheme’s success hinges on addressing systemic issues and involving all stakeholders. As PM-JAY continues to be implemented, understanding the politics, power dynamics, and structural issues that shaped its formulation will be crucial.

Reference url

Recent Posts

South Africa Health Reform: Revitalizing the Crisis-Stricken Sector

By João L. Carapinha

March 26, 2026

South Africa health reform is urgently needed to reverse the deepening crisis in the country’s public and private health sectors. Sustained real-term declines in public per-capita spending, massive provincial debt, critical staff shortages, and uncontrolled private-sector cost escalation are coll...
PEPFAR TB Impact: Averting Millions of Cases and Deaths Among HIV Patients

By HEOR Staff Writer

March 25, 2026

PEPFAR TB Impact has been profound, with the U.S. President’s Emergency Plan for AIDS Relief averting an estimated 11.0 million tuberculosis (TB) cases and 2.1 million TB-related deaths among persons with HIV between 2003 and 2024. The PEPFAR TB impact extends far beyond HIV, delivering substa...
Citation Analysis of Real-World Evidence in Medicare Drug Price Negotiations

By João L. Carapinha

March 24, 2026

Medicare Drug Price Negotiations are increasingly relying on real-world evidence, according to a new citation analysis of the first drugs selected under the Inflation Reduction Act. The study examined how the Centers for Medicare and Medicaid Services (CMS) uses real-world evidence (RWE) in its M...